488 related articles for article (PubMed ID: 30099051)
41. "Molecular switches" on mGluR allosteric ligands that modulate modes of pharmacology.
Wood MR; Hopkins CR; Brogan JT; Conn PJ; Lindsley CW
Biochemistry; 2011 Apr; 50(13):2403-10. PubMed ID: 21341760
[TBL] [Abstract][Full Text] [Related]
42. Subtype-selective mechanisms of negative allosteric modulators binding to group I metabotropic glutamate receptors.
Fu TT; Tu G; Ping M; Zheng GX; Yang FY; Yang JY; Zhang Y; Yao XJ; Xue WW; Zhu F
Acta Pharmacol Sin; 2021 Aug; 42(8):1354-1367. PubMed ID: 33122823
[TBL] [Abstract][Full Text] [Related]
43. In vitro and in vivo characterization of MPEP, an allosteric modulator of the metabotropic glutamate receptor subtype 5: review article.
Kuhn R; Pagano A; Stoehr N; Vranesic I; Flor PJ; Lingenhöhl K; Spooren W; Gentsch C; Vassout A; Pilc A; Gasparini F
Amino Acids; 2002; 23(1-3):207-11. PubMed ID: 12373539
[TBL] [Abstract][Full Text] [Related]
44. Virtual Screening and Molecular Dynamics Study of Potential Negative Allosteric Modulators of mGluR1 from Chinese Herbs.
Jiang L; Zhang X; Chen X; He Y; Qiao L; Zhang Y; Li G; Xiang Y
Molecules; 2015 Jul; 20(7):12769-86. PubMed ID: 26184151
[TBL] [Abstract][Full Text] [Related]
45. Allosteric agonists of 7TM receptors: expanding the pharmacological toolbox.
Langmead CJ; Christopoulos A
Trends Pharmacol Sci; 2006 Sep; 27(9):475-81. PubMed ID: 16889837
[TBL] [Abstract][Full Text] [Related]
46. Functional impact of allosteric agonist activity of selective positive allosteric modulators of metabotropic glutamate receptor subtype 5 in regulating central nervous system function.
Noetzel MJ; Rook JM; Vinson PN; Cho HP; Days E; Zhou Y; Rodriguez AL; Lavreysen H; Stauffer SR; Niswender CM; Xiang Z; Daniels JS; Jones CK; Lindsley CW; Weaver CD; Conn PJ
Mol Pharmacol; 2012 Feb; 81(2):120-33. PubMed ID: 22021324
[TBL] [Abstract][Full Text] [Related]
47. Recent Advances in the Drug Discovery and Development of Dualsteric/ Bitopic Activators of G Protein-Coupled Receptors.
Reinecke BA; Wang H; Zhang Y
Curr Top Med Chem; 2019; 19(26):2378-2392. PubMed ID: 31833462
[TBL] [Abstract][Full Text] [Related]
48. Integrated In Silico Fragment-Based Drug Design: Case Study with Allosteric Modulators on Metabotropic Glutamate Receptor 5.
Bian Y; Feng Z; Yang P; Xie XQ
AAPS J; 2017 Jul; 19(4):1235-1248. PubMed ID: 28560482
[TBL] [Abstract][Full Text] [Related]
49. Synergy between L-DOPA and a novel positive allosteric modulator of metabotropic glutamate receptor 4: implications for Parkinson's disease treatment and dyskinesia.
Bennouar KE; Uberti MA; Melon C; Bacolod MD; Jimenez HN; Cajina M; Kerkerian-Le Goff L; Doller D; Gubellini P
Neuropharmacology; 2013 Mar; 66():158-69. PubMed ID: 22491024
[TBL] [Abstract][Full Text] [Related]
50. Pharmacology of Free Fatty Acid Receptors and Their Allosteric Modulators.
Grundmann M; Bender E; Schamberger J; Eitner F
Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33578942
[TBL] [Abstract][Full Text] [Related]
51. Metabotropic glutamate receptors as therapeutic targets for schizophrenia.
Vinson PN; Conn PJ
Neuropharmacology; 2012 Mar; 62(3):1461-72. PubMed ID: 21620876
[TBL] [Abstract][Full Text] [Related]
52. Biased allosteric agonism and modulation of metabotropic glutamate receptor 5: Implications for optimizing preclinical neuroscience drug discovery.
Sengmany K; Singh J; Stewart GD; Conn PJ; Christopoulos A; Gregory KJ
Neuropharmacology; 2017 Mar; 115():60-72. PubMed ID: 27392634
[TBL] [Abstract][Full Text] [Related]
53. Photoswitchable allosteric modulators for metabotropic glutamate receptors.
Gómez-Santacana X; Panarello S; Rovira X; Llebaria A
Curr Opin Pharmacol; 2022 Oct; 66():102266. PubMed ID: 35870289
[TBL] [Abstract][Full Text] [Related]
54. The Quantitative Characterization of Functional Allosteric Effects.
Kenakin T
Curr Protoc Pharmacol; 2017 Mar; 76():9.22.1-9.22.10. PubMed ID: 28306151
[TBL] [Abstract][Full Text] [Related]
55. Leveraging allostery to improve G protein-coupled receptor (GPCR)-directed therapeutics: cannabinoid receptor 1 as discovery target.
Janero DR; Thakur GA
Expert Opin Drug Discov; 2016 Dec; 11(12):1223-1237. PubMed ID: 27712124
[TBL] [Abstract][Full Text] [Related]
56. Pharmacology of metabotropic glutamate receptor allosteric modulators: structural basis and therapeutic potential for CNS disorders.
Gregory KJ; Noetzel MJ; Niswender CM
Prog Mol Biol Transl Sci; 2013; 115():61-121. PubMed ID: 23415092
[TBL] [Abstract][Full Text] [Related]
57. A novel family of potent negative allosteric modulators of group II metabotropic glutamate receptors.
Hemstapat K; Da Costa H; Nong Y; Brady AE; Luo Q; Niswender CM; Tamagnan GD; Conn PJ
J Pharmacol Exp Ther; 2007 Jul; 322(1):254-64. PubMed ID: 17416742
[TBL] [Abstract][Full Text] [Related]
58. GPCR drug discovery: novel ligands for CNS receptors.
Lim WK
Recent Pat CNS Drug Discov; 2007 Jun; 2(2):107-12. PubMed ID: 18221221
[TBL] [Abstract][Full Text] [Related]
59. Selective Negative Allosteric Modulation Of Metabotropic Glutamate Receptors – A Structural Perspective of Ligands and Mutants.
Harpsøe K; Isberg V; Tehan BG; Weiss D; Arsova A; Marshall FH; Bräuner-Osborne H; Gloriam DE
Sci Rep; 2015 Sep; 5():13869. PubMed ID: 26359761
[TBL] [Abstract][Full Text] [Related]
60. Recent progress on the identification of metabotropic glutamate 4 receptor ligands and their potential utility as CNS therapeutics.
Robichaud AJ; Engers DW; Lindsley CW; Hopkins CR
ACS Chem Neurosci; 2011 Aug; 2(8):433-49. PubMed ID: 22860170
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
